H.C. Wainwright raised the firm’s price target on BioLife Solutions (BLFS) to $30 from $27 and keeps a Buy rating on the shares following the Q4 beat. The firm says the company’s cell processing platform has delivered five consecutive quarters of revenue growth. The firm cites BioLife’s “strong financial performance” for the higher target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- BioLife Solutions Inc.: Focus on Growth Over Dividends May Limit Immediate Investor Returns
- BioLife Solutions Reports Strong 2024 Financial Growth
- BioLife Solutions Inc. Projects Strong 2025 Growth
- BioLife Solutions: Promising Financial Outlook and Strategic Positioning Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue